Relative Bioavailability of a 12.5 mg BI 10773 / 1000 mg Metformin Fixed Dose Combination Tablet Compared With Its Monocomponents and Administered With and Without Food (an Open-label, Randomised, Single-dose, Three-way Crossover, Phase I Trial in Healthy Volunteers)
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2015
At a glance
- Drugs Empagliflozin/metformin (Primary) ; Empagliflozin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 20 Dec 2010 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 20 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2010 New trial record